Dragging ras back in the ring.

By A. Stephen, Dominic Esposito, R. Bagni, F. McCormick. Cancer Cell, 2014

772 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations (2015, background): “These concepts, coupled with a renewed enthusiasm around the idea of targeting KRAS (10) have motivated us to study the critical question—Are the biologic behaviors of specific KRASmutations measurably different and is it possible to subclassify specific KRAS-containing tumors based on biochemical b”
Drugging the ‘undruggable’ cancer targets (2017, positive): “…which are related to RAS, mediate their effects by binding to multiple effectors, and some of these genes, such as those encoding Gα12 and Gα13, are mutated in several cancers and constitute important cancer targets 9 . compared with 53,700 and 39,100 for KRAS G12D and KRAS G12V , respectively 10 .”
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer (2018, neutral): “2C) (Cox et al. 2014; Stephen et al. 2014; Hobbs et al. 2016).”